A Phase 1 interventional study of BAY 3547926 and BAY 3547922 in Hepatocellular Carcinoma, sponsored by Bayer. Recruiting at 36 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Bayer · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Carcinoma, Hepatocellular by Bayer — 1 open to participants now, 2 under way, none of them phase 3. Carcinoma, Hepatocellular · Bayer.
Among the 34 studies in Carcinoma, Hepatocellular by Bayer, this one is the 9th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2025, is one of 4 in phase 1, and was the 34th registered.
3,652 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.
Browse Carcinoma, Hepatocellular studies →1 of the 34 studies in Carcinoma, Hepatocellular by Bayer is open now, in 9 countries.
By country, each count listing its studies:
Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 148 is above the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 117 across the 20 interventional studies, 301 across the 14 observational. Of the 31 that completed or were terminated, 12 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 34 studies in Carcinoma, Hepatocellular by Bayer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this study, researchers want to learn about the safety of a new drug, BAY 3547926, and how well the drug works in people with a type of liver cancer called advanced hepatocellular carcinoma (HCC), which has a special protein called Glypican 3 (GPC3). Researchers want to find the best dose of BAY 3547926 for people with advanced HCC and look at the way the body absorbs and distributes the drug.
The study drug, BAY 3547926, delivers a radioactive agent to cancer cells. The radioactive agent emits radiations which can damage the cancer cells and cause them to die. These radiations travel a small distance, so are expected to cause little damage to surrounding healthy tissues. This is the first study of BAY 3547926 in humans.
Participants will take part in one of the 4 different parts of the study. In Part 1, participants will receive different doses of BAY 3547926 alone to find the dose that is deemed safe and works best for the participants. When this dose has been found, a larger number of participants will receive BAY 3547926 alone in Part 2 or with other treatments in Parts 3 and 4 of the study.
During the study, the doctors and their study team will do health check-ups, take pictures (scans) of the body, collect blood and urine samples, and ask participants questions about how they are feeling and what health problems they are having.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
actinium-225 labeled antibody conjugate
Drug: BAY 3547926 · Drug: BAY 3547922 · Drug: BAY 3713391 · Drug: BAY 3713389
antibody conjugate with actinium-225 label
antibody conjugate without actinium-225 label as preinjection
Radioactive imaging agent - optional preinjection
optional preinjection
Part 1 (dose escalation): Occurrence and severity of TEAEs
TEAE=Treatment emergent adverse event
Time frame: up to 60 months after first administration
Part 1 (dose escalation): Recommended safe and active dose (RSAD)
The RSAD is based on incidence of DLT and preliminary anti-tumor activity (ORR using RECIST 1.1 by Investigator assessment) informed by TITE-CRM. RSAD=Recommended safe and active dose DLT=Dose limiting toxicity ORR=Objective reponse rate RECIST=Response Evaluation Criteria in Solid Tumors TITE-CRM =Time-to-event continual reassessment method
Time frame: up to 60 months after first administration
Part 2 (dose expansion): Occurrence and severity of TEAEs
TEAE=Treatment emergent adverse event
Time frame: up to 60 months after first administration
Part 2 (dose expansion): ORR using RECIST 1.1 by investigator assessment
ORR=Objective reponse rate RECIST=Response Evaluation Criteria in Solid Tumors
Time frame: up to 60 months after first administration
Part 2 (dose expansion): DCR using RECIST 1.1 by investigator assessment
DCR=Disease control rate RECIST=Response Evaluation Criteria in Solid Tumors
Time frame: up to 60 months after first administration
Part 2 (dose expansion): DoR using RECIST 1.1 by investigator assessment
DoR=Duration of response RECIST=Response Evaluation Criteria in Solid Tumors
Time frame: up to 60 months after first administration
Part 2 (dose expansion): PFS using RECIST 1.1 by investigator assessment
PFS=Progression free survival RECIST=Response Evaluation Criteria in Solid Tumors
Time frame: up to 60 months after first administration
Parts 3 and 4 (dose expansion in combination): Occurrence and severity of TEAEs
TEAE=Treatment emergent adverse event
Time frame: up to 60 months after first administration
Parts 3 and 4 (dose expansion in combination): ORR using RECIST 1.1 by investigator assessment
ORR= Objective response rate
Time frame: up to 60 months after first administration
Parts 3 and 4 (dose expansion in combination): DCR using RECIST 1.1 by investigator assessment
DCR=Disease control rate
Time frame: up to 60 months after first administration
Parts 3 and 4 (dose expansion in combination): DoR using RECIST 1.1 by investigator assessment
DoR=Duration of response
Time frame: up to 60 months after first administration
Parts 3 and 4 (dose expansion in combination): PFS using RECIST 1.1 by investigator assessment
PFS=Progression free survivial
Time frame: up to 60 months after first administration
Part 1 (dose escalation): Recommended dose level(s) based on occurrence and severity of TEAEs and DLTs, PK, immunogenicity, and preliminary anit-tumor activity (ORR using RECIST 1.1 by Investigator assessment)
TEAE=Treatment emergent adverse event DLT=Dose limiting toxicity PK=Pharmacokinetic ORR=Objective response rate RECIST=Response Evaluation Criteria in Solid Tumors
Time frame: up to 60 months after first administration
Part 1 (dose escalation): Recommended dosing regimen based on occurrence and severity of TEAEs and DLTs, PK, immunogenicity, and preliminary anti-tumor activity (ORR using RECIST 1.1 by Investigator assessment)
TEAE=Treatment emergent adverse event DLT=Dose limiting toxicity PK=Pharmacokinetic ORR=Objective response rate RECIST=Response Evaluation Criteria in Solid Tumors
Time frame: up to 60 months after first administration
Part 1 (dose escalation): ORR using RECIST 1.1 by investigator assessment
ORR=Objective response rate RECIST=Response Evaluation Criteria in Solid Tumors
Time frame: up to 60 months after first administration
Part 1 (dose escalation): DCR using RECIST 1.1 by investigator assessment
DCR=Disease control rate RECIST=Response Evaluation Criteria in Solid Tumors
Time frame: up to 60 months after first administration
Part 1 (dose escalation): DoR using RECIST 1.1 by investigator assessment
DoR=Duration of response RECIST=Response Evaluation Criteria in Solid Tumors
Time frame: Up to 60 months after first administration
Part 1 (dose escalation): PFS using RECIST 1.1 by investigator assessment
PFS=Progression free survival RECIST=Response Evaluation Criteria in Solid Tumors
Time frame: up to 60 months after first administration
Part 1 (dose escalation): Cmax of BAY 3547926 after a single dose and after multiple doses
Cmax=Maximal blood concentration
Time frame: up to 36 weeks after first administration
Part 1 (dose escalation): AUC of BAY 3547926 after a single dose and after multiple doses
AUC=Area under the blood concentration versus time curve
Time frame: up to 36 weeks after first administration
Part 1 (dose escalation): Clearance of BAY 3547926 after a single dose and after multiple doses if data allow
PK=Pharmacokinetic
Time frame: up to 36 weeks after first administration
Part 2 (dose expansion): Recommended dose based on safety, PK, IG and markers of pharmacodynamic activity and efficacy assessments
PK=Pharmacokinetic IG=Immunogenicity
Time frame: up to 36 months after first administration
Part 2 (dose expansion): Recommended schedule based on safety, PK, IG and markers of pharmacodynamic activity and efficacy assessments
PK=Pharmacokinetic IG=Immunogenicity
Time frame: up to 36 months after first administration
Part 2 (dose expansion): Cmax of BAY 3547926 after a single dose and after multiple doses
Cmax=maximal blood concentration
Time frame: up to 36 weeks after first administration
Part 2 (dose expansion): AUC of BAY 3547926 after a single dose and after multiple doses
AUC=Area under curve of blood concentration versus time curve
Time frame: up to 36 weeks after first administration
Part 2 (dose expansion): Clearance of BAY 3547926 after single dose and after multiple doses, where applicable and if data allow
PK=Pharmacokinetic
Time frame: up to 36 weeks after first administration
Parts 3 and 4 (dose expansion in combination): Recommended dose level(s) of BAY 3547926 based on clinical data including, but not limited to, occurrence and severity of TEAEs and DLTs, PK and IG
TEAE=Treatment emergent adverse event DLT=Dose limiting toxicity PK=Pharmacokinetic IG=Immunogenicity
Time frame: up to 60 months after first administration
Parts 3 and 4 (dose expansion in combination): Recommended dosing regimen of BAY 3547926 based on clinical data including, but not limited to, occurrence and severity of TEAEs and DLTs, PK and IG
TEAE=Treatment emergent adverse event DLT=Dose limiting toxicity PK=Pharmacokinetic IG=Immunogenicity
Time frame: up to 60 months after first administration
Parts 3 and 4 (dose expansion in combination): Recommended schedule of BAY 3547926 based on severity of TEAEs, PK, IG
TEAE=Treatment emergent adverse event DLT=Dose limiting toxicity PK=Pharmacokinetic IG=Immunogenicity
Time frame: up to 60 months after first administration
Parts 3 and 4 (dose expansion in combination): Cmax of BAY 3547926 after a single dose and after multiple doses of BAY 3547926 in combination
Cmax=maximal blood concentration
Time frame: up to 60 months after first administration
Parts 3 and 4 (dose expansion in combination): AUC of BAY 3547926 after single dose and after multiple doses of BAY 3547926 in combination
AUC=Area under curve of blood concentration versus time curve
Time frame: up to 60 months after first administration
Parts 3 and 4 (dose expansion in combination): Clearance of BAY 3547926 after single dose and after multiple doses of BAY 3547926 in combination, where applicable and if data allow
PK=Pharmacokinetic
Time frame: up to 60 months after first administration
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Jul 2029, 53 months after the start.
Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 53 months is above that.
Counting every sponsor, half of 250 studies reached it within 49 months; a quarter within 32 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.